Preventive Washing in ICU: Evidence-Based Infection Prevention

Healthcare-associated infections (HCAIs) remain one of the biggest challenges in modern healthcare — affecting up to 37%¹ of ICU patients and costing the NHS £2.7 billion each year².

According to the World Health Organization (WHO), up to 70% of infections can be prevented through effective infection prevention and control³. Preventive washing is emerging as one of the simplest, evidence-based steps to help protect patients, reduce antibiotic use, and strengthen infection prevention across hospitals.

To explore this topic further, experts Dr Philipp Walloch and Dr Roger Henderson share their insights in a three-part podcast series, discussing practical, evidence-based measures that make a difference.

Critically ill patients are especially vulnerable to infection due to weakened immune systems and invasive procedures⁴. Up to 37% of ICU patients develop an HCAI¹ — increasing the risk of complications, longer stays, and mortality⁵.

Key Facts:

• HCAIs affect 7.6% of patients in hospitals²
• Cost the NHS £2.7 billion each year²
• Cause 834,000 infections and 28,500 deaths annually²
• Bloodstream infection prevalence in ICU: 34%⁴
• WHO: IPC measures reduce HCAIs and AMR by 35–70%³

A simple, evidence-based step toward safer care. For ICU patients, preventive washing with antiseptic products may help lower the risk of bloodstream infections⁶ and multidrug-resistant organisms (MDROs)⁷.

Two key approaches:

1. Targeted decontamination – for patients testing positive for Staphylococcus aureus
2. Universal decontamination – for all ICU admissions

Research shows universal decontamination can prevent up to 45% of MRSA infections⁸, improving outcomes hospital-wide⁹.

A three-part conversation tackling one critical question: can preventive washing reduce ICU infections? In this engaging series, Dr Philipp Walloch and Dr Roger Henderson discuss the global challenge of antimicrobial resistance (AMR), the role of infection prevention, and the evidence supporting antiseptic bathing as a simple, effective strategy for ICU teams.

Each episode explores a vital theme:

• The Connection Between AMR and HCAIs – how resistance and infections go hand in hand.
• Prevention Over Treatment – why every infection prevented avoids another antibiotic course.
• The EFFECT Study – large-scale evidence showing antiseptic bathing reduces bloodstream infections by 17%.

Octenidine-based antimicrobial wash mitts have been shown to:

• Reduce ICU-acquired bloodstream infections and MRSA⁶
• Deliver a 17% reduction in bacteraemia compared to placebo¹⁰
• Lower antibiotic prescriptions and unwarranted infections¹¹
• Improve patient and staff satisfaction through waterless convenience¹²

Octenidine benefits:

• Broad-spectrum antimicrobial action¹³
• No known resistance¹⁰
• Excellent skin compatibility¹⁴
• Lasting protection for up to 48 hours¹⁵